TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02130687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Test (MMT)
Description: The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Meal Test (MMT)
Description: The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Test (MMT)
Description: The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
Study: NCT05047029

Intervention type: PROCEDURE
Intervention: Transjugular intrahepatic portosystemic shunt implantation
Description: Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Multiparametric cardiac and hepatic magnetic resonance imaging
Study: NCT03134495

Intervention type: OTHER
Intervention: all children with at least one prescription of PPI
Description: all children with at least one prescription of PPI

Intervention type: OTHER
Intervention: all children with no prescription of PPI
Description: all children with no prescription of PPI
Study: NCT02829450

Intervention type: OTHER
Intervention: peritoneal ultrafiltration
Description: Peritoneal fluids should be inserted intraperitoneally for several hours dwell
Study: NCT00516438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: intravenous infusion
Study: NCT02606604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RT 300: Lower Extremity Cycling
Description: Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT 300: Lower Extremity Cycling
Description: Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
Study: NCT03348033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chronic Myeloid Leukemia + NK cell
Description: Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
Study: NCT03520803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery protocol
Description: Experimental enhanced recovery protocol for pre-surgery and post surgery
Study: NCT03146715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feeding trial
Description: Children were asked to eat the designated portion of the assigned food once a day for six weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding trial
Description: Children were asked to eat the designated portion of the assigned food once a day for six weeks.
Study: NCT02130973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Practice Regimen
Description: Standard Clinical Practice Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Cyclic Regimen
Description: Experimental Cyclic Regimen
Study: NCT04616183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERK1/2 Inhibitor LY3214996
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERK1/2 Inhibitor LY3214996
Description: Given PO
Study: NCT02375737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-health
Description: Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
Study: NCT05834933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized breast cancer risk assessment
Description: Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized breast cancer risk counselling
Description: Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
Study: NCT01522521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK156
Description: zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (i.v.)/year + daily calcium and vitamin D for 2 years
Study: NCT03563677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual expert guidance structure
Description: Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
Study: NCT04246437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FDOPA
Description: Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa 200mg oral dose
Description: 30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone 400mg oral dose
Description: 30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
Study: NCT02840370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
Study: NCT04384328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Support Programme in Orthophony
Description: Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
Study: NCT01266954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
Study: NCT03578081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Hydrochloride
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant Dimeglumine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV
Study: NCT00974441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: 500 mg Extended Release Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote®
Description: 500 mg Extended Release Tablet
Study: NCT00949754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: honeybee venom (Apitoxin (Korea) Apitox (USA))
Description: multiple intradermal injections of 100 ug pure honeybee venom

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: honeybee venom (Apitoxin (Korea) Apitox (USA))
Description: multiple intradermal injections of 100 ug pure honeybee venom
Study: NCT01536665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
Study: NCT00946764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
Study: NCT00308412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV3cp45
Description: Placebo for rHPIV3cp45 vaccine is 1X L-15.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rHPIV3cp45 vaccine
Study: NCT01274923

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MEDISPEC treatment probe
Description: shock wave treatment
Study: NCT03096912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
Study: NCT00386633

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MVA-mBN32
Description: 3 immunizations; first study group: 10E7_TCID50

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-mBN32
Description: 3 immunizations; second study group: 10E8_TCID50
Study: NCT01866098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00701961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate
Description: Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine-artesunate
Description: Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
Study: NCT00865371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrika Bupropion 150 mg Extended-Released Tablet
Description: A: Experimental Subjects received Abrika formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
Study: NCT03649347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented reality exposure therapy
Description: Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
Study: NCT03431350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Description: Participants will receive niraparib 200 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Description: Participants will receive niraparib 200 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Description: Participants will receive niraparib 200 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Description: Participants will receive niraparib 200 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 240 mg
Description: Participants will receive cetrelimab 240 mg IV every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Participants will receive cetrelimab 480 mg IV every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Participants will receive cetrelimab 480 mg IV every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg
Description: Participants will receive AA 1000 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg
Description: Participants will receive AA 1000 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: Participants will receive prednisone 5 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: Participants will receive prednisone 5 mg orally.
Study: NCT04277637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Film-coated tablets administered once daily at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Film-coated tablets administered once daily at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Film-coated tablets administered once daily at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Film-coated tablets administered once daily at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Film-coated tablets administered once daily at a dose as specified in the treatment arm
Study: NCT01555671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: 0.5 ml meperidine injection intravenously injected in randomly selected patients
Study: NCT04277637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Film-coated tablets administered once daily at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given as an intravenous infusion administered per label.
Study: NCT01555671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5 ml saline solution injection intravenously injected in randomly selected patients
Study: NCT00976911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal doxorubicin
Description: 40mg/m2 iv every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 40mg/m2 iv every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
Study: NCT04026009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)
Description: Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)
Description: Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B
Description: Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
Study: NCT03289663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synergistic combination of insecticides
Description: third generation insecticide -treated bednets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrethroids
Description: Conventional insecticide
Study: NCT04966494

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOSB
Description: BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.
Study: NCT03319563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic-epinephrine
Description: * Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: normal saline 100 ml/10 cm of the wound length
Study: NCT01152047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: 40mU/min as infusion of oxytocin